MRK logo

Merck & Co., Inc.

MRK
Healthcare|Drug Manufacturers - General|US
$146.71
-0.23 (-0.16%)
DCF Value
$180.27
Graham Number
$20.09
Cash / Share
$3.89
Next Earnings Report
Feb 2, 2027
EPS est. $1.78 · Revenue est. $16.29B
Financing Filings (last 12 months)
4
Shelf registrations / offering prospectuses — latest May 20, 2026 (424B5). Possible dilution.

Upcoming Data Readouts (49)

Nov 2026
Est. completion
P1Acute Myeloid Leukemia
Venetoclax and Bomedemstat in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Dec 2026
Est. completion
Invasive Fungal Disease
FungiScope - A Global Emerging Fungal Infection Registry
Dec 2026
Est. completion
COVID-19
ARMOR-Household: Characterizing Transmission of COVID-19 in Households of SARS-CoV-2 Index Cases
Dec 2026
Est. completion
P1P2Primary Central Nervous System Lymphoma
Pembrolizumab, Ibrutinib and Rituximab in PCNSL
Dec 2026
Est. completion
P2Uterine Carcinosarcoma
A Study of Pembrolizumab With Lenvatinib in Women With Advanced Uterine Carcinosarcoma
Dec 2026
Est. completion
P1Healthy Participants
A Trial to Evaluate the Effect of CD388/MK1406 on the Immunogenicity of Fluzone® HD Vaccine (CD388.SQ.1.08/MK-1406-007)
Dec 2026
Est. completion
P1Multiple Myeloma in Relapse
Study of HPN217 in Participants With Relapsed/Refractory Multiple Myeloma MK-4002 (MK-4002-001)
Jan 2027
Est. completion
P2Squamous Cell Carcinoma of Head and Neck
Pembrolizumab Plus Olaparib in LA-HNSCC
Jan 2027
Est. completion
P3Urothelial Carcinoma
Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2
Jan 2027
Est. completion
P2Tumor
Evaluation of the Response and Non-response of Nirogacestat in Desmoid Tumors- Clinical Study
Feb 2027
Est. completion
P2Renal Cell Carcinoma (RCC)
A Trial of Belzutifan (PT2977, MK-6482) in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC) (MK-6482-003)
Mar 2027
Est. completion
P2Pulmonary Disease, Chronic Obstructive, COPD
Effect of Ensifentrine (MK-5884/RPL554) on Sputum Markers of Inflammation in Chronic Obstructive Pulmonary Disease (COPD) (MK-5884-023/RPL554-CO-207)
Apr 2027
Est. completion
P1P2Carcinoma, Non-Small-Cell Lung
Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)
Apr 2027
Est. completion
P1P2Chronic Lymphocytic Leukemia
Study to Evaluate the Safety and Preliminary Efficacy of Ibrutinib and Pembrolizumab in Patients With Chronic Lymphocytic Leukemia (CLL) or Mantle Cell Lymphoma (MCL)
Apr 2027
Est. completion
P2Bladder Cancer
Pembrolizumab (MK-3475) and Bacillus Calmette-Guérin (BCG) as First-Line Treatment for High-Risk T1 Non-Muscle-Invasive Bladder Cancer (NMIBC) and High-Grade Non-Muscle-Invasive Upper Tract Urothelial Carcinoma (NMI-UTUC)]
Apr 2027
Est. completion
P2VHL - Von Hippel-Lindau Syndrome
A Phase 2 Study of Belzutifan (PT2977, MK-6482) for the Treatment of Von Hippel Lindau (VHL) Disease-Associated Renal Cell Carcinoma (RCC) (MK-6482-004)
Apr 2027
Est. completion
P1P2Advanced Solid Tumor
Study of Ifinatamab Deruxtecan (DS-7300a, I-DXd) in Participants With Advanced Solid Malignant Tumors
Jun 2027
Est. completion
P3Influenza
A Study to Evaluate the Safety and Efficacy of MK-1406/CD388 for Prevention of Influenza (MK-1406-005/CD388.SQ.3.06)
NCT07159763n=10,000
Jul 2027
Est. completion
P1P2Bladder Cancer
A Clinical Study of MK-3120 in People With Bladder Cancer (MK-3120-003)
Jul 2027
Est. completion
P2Healthy Participants
A Study of Annual Doses of MK-1406/CD388 in Healthy Adults (MK-1406-006/CD388.SQ.2.07)

Awaiting Results (26)

Trials past primary completion date but still active — data readout may be imminent.

Nov 2026
P4
REVIVE (Response to the Ebola Virus Vaccine)
NCT05992480
Oct 2026
P2
IMG-7289 in Patients With Essential Thrombocythemia (ET) or Polycythemia Vera (PV)
NCT04262141
Aug 2026
P3
A Study to Evaluate Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderately to Severely Active Ulcerative Colitis (MK-7240-001)
NCT06052059
May 2026
P2
Pembrolizumab in Combination With R-ICE Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma
NCT05221645
Apr 2026
P2
Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD) (MK-7240-007)
NCT05270668
Apr 2026
P2
Study to Evaluate Tulisokibart for Hidradenitis Suppurativa (MK-7240-012)
NCT06956235
Mar 2026
P2
Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors
NCT03485209
Feb 2026
P3
A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011)
NCT04586231
Dec 2025
P1
U3-1402 in Metastatic or Unresectable Non-Small Cell Lung Cancer
NCT03260491
Dec 2025
P1
A Phase 1b Trial to Evaluate Safety of MB097 in Combination With Pembrolizumab in Melanoma Patients
NCT06540391

Recent Press Releases

SEC Filings (69)

Last two years from EDGAR. Insider Form 4s are on the Ownership tab.

FiledFormWhat it isLinks
Nov 4, 202610-QQuarterly reportDocumentIndex
Oct 29, 20268-KMaterial eventDocumentIndex
Oct 15, 202625-NSEDocumentIndex
Oct 13, 20268-KMaterial eventDocumentIndex
Aug 7, 202610-QQuarterly reportDocumentIndex
Aug 7, 202613F-HRInstitutional holdings reportDocumentIndex
Aug 4, 20268-KMaterial eventDocumentIndex
Jun 24, 202611-KDocumentIndex
Jun 24, 202611-KDocumentIndex
Jun 24, 202611-KDocumentIndex
May 29, 2026SDDocumentIndex
May 28, 20268-KMaterial eventDocumentIndex
May 22, 20268-KMaterial eventDocumentIndex
May 20, 2026424B5Offering prospectusDocumentIndex
May 19, 2026FWPDocumentIndex
May 18, 2026424B5Offering prospectusDocumentIndex
May 13, 202613F-HRInstitutional holdings reportDocumentIndex
May 5, 2026SC TO-T/ATender offerDocumentIndex
May 4, 202610-QQuarterly reportDocumentIndex
Apr 30, 2026SC 13GPassive 5%+ stakeDocumentIndex
Apr 30, 20268-KMaterial eventDocumentIndex
Apr 24, 2026SC TO-T/ATender offerDocumentIndex
Apr 8, 2026ARSAnnual report to holdersDocumentIndex
Apr 8, 2026DEFA14AProxy / shareholder voteDocumentIndex
Apr 8, 2026DEF 14AProxy / shareholder voteDocumentIndex
Apr 7, 2026SC TO-TTender offerDocumentIndex
Mar 27, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Feb 24, 202610-KAnnual reportDocumentIndex
Feb 17, 202613F-HRInstitutional holdings reportDocumentIndex
Feb 3, 20268-KMaterial eventDocumentIndex
Jan 7, 2026SC TO-T/ATender offerDocumentIndex
Dec 19, 2025SC TO-T/ATender offerDocumentIndex
Dec 17, 2025SC TO-T/ATender offerDocumentIndex
Dec 5, 2025SC TO-TTender offerDocumentIndex
Dec 4, 20258-KMaterial eventDocumentIndex
Dec 3, 2025424B5Offering prospectusDocumentIndex
Dec 2, 2025FWPDocumentIndex
Dec 1, 2025424B5Offering prospectusDocumentIndex
Nov 12, 202513F-HRInstitutional holdings reportDocumentIndex
Nov 5, 202510-QQuarterly reportDocumentIndex